Zevra Therapeutics Inc
ZVRAHealthcare|Biotechnology|USA
$13.34
-0.59 (-4.23%)
Tangible Book
$3.30
Financials
Financial Snapshot
Market Cap
$788.3M
Enterprise Value
$199.5M
Revenue (TTM)
$122.3M
Net Income (TTM)
$124.2M
Cash & Equivalents
—
Net Cash/Share
$2.16
Free Cash Flow (TTM)
$12.0M
Operating CF (TTM)
$12.8M
Debt/Equity
0.01
Cash Runway & Burn Rate
Company is cash-flow positive.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $67.8M | $42.2M | $21.7M | $3.2M | $4.2M | $112.3M | $82.8M | $67.7M | $69.5M | $191.0M | $200.6M | |
| Operating Cash Flow | $-29.8M | $-33.1M | $-54.2M | $-23.7M | $-1.9M | $10.4M | $-18.7M | $-33.5M | $-69.7M | $-1.6M | $12.8M | |
| Free Cash Flow | $-30.4M | $-33.3M | $-54.2M | $-23.8M | $-2.0M | $10.3M | $-18.8M | $-33.8M | $-69.7M | $-2.4M | $12.0M | |
| Capital Expenditure | $-643.0K | $-181.0K | $-21.0K | $-26.0K | $-33.0K | $-102.0K | $-93.0K | $-296.0K | $0.00 | $-835.0K | $-771.0K | |
| Financing Cash Flow | $61.2M | $-203.0K | $28.0M | $4.9M | $2.7M | $113.1M | $8.4M | $28.5M | $82.1M | $12.1M | $-42.3M |
R&D Spending
R&D (TTM)
$13.9M
R&D Intensity
11.3%
R&D Growth YoY
+8.9%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $12.8M | $13.3M | $28.6M | $10.2M | $27.5M | $23.6M | $106.5M | $122.3M | |
| R&D Expense | $20.5M | $20.6M | $41.8M | $19.4M | $8.8M | $10.2M | $19.8M | $39.8M | $42.1M | $12.7M | $13.9M | |
| R&D % of Revenue | — | — | — | 151.2% | 66.5% | 35.5% | 194.9% | 145.0% | 178.3% | 12.0% | 11.3% | |
| SG&A | $14.0M | $12.8M | $12.5M | $10.8M | $7.9M | $8.7M | $15.0M | $34.3M | $54.9M | $77.6M | $78.9M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $12.8M | $13.3M | $28.6M | $10.2M | $27.5M | $23.6M | $106.5M | $122.3M | |
| Cost of Goods Sold | $0.00 | $0.00 | $0.00 | $2.9M | $1.3M | $2.1M | $222.0K | $2.2M | $7.4M | $16.5M | $17.0M | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $9.9M | $12.0M | $26.6M | $9.9M | $25.3M | $16.2M | $90.0M | $105.3M | |
| R&D | $20.5M | $20.6M | $41.8M | $19.4M | $8.8M | $10.2M | $19.8M | $39.8M | $42.1M | $12.7M | $13.9M | |
| SG&A | $14.0M | $12.8M | $12.5M | $10.8M | $7.9M | $8.7M | $15.0M | $34.3M | $54.9M | $77.6M | $78.9M | |
| Operating Income | $-34.5M | $-33.4M | $-54.3M | $-20.3M | $-4.8M | $7.7M | $-24.9M | $-49.6M | $-87.0M | $-4.2M | $10.0M | |
| Interest Expense | $-7.1M | $-7.3M | $-7.1M | $-6.5M | $-7.1M | $-376.0K | $-335.0K | $-1.5M | $-7.4M | $-8.0M | $-7.7M | |
| Pretax Income | $-16.5M | $-43.4M | $-56.6M | $-24.5M | $-12.8M | $-8.5M | $-26.8M | $-46.0M | $-90.1M | $86.7M | $133.4M | |
| Net Income | $-16.5M | $-43.4M | $-56.5M | $-24.5M | $-12.8M | $-8.6M | $-26.8M | $-46.0M | $-105.5M | $83.2M | $124.2M | |
| EPS (Diluted) | -18.08 | -47.36 | -50.40 | -13.23 | -3.21 | -2.11 | -0.78 | -1.30 | -2.28 | 1.35 | 1.99 | |
| EBITDA | $-9.2M | $-35.8M | $-49.2M | $-17.7M | $-5.4M | $-7.9M | $-25.5M | $-43.5M | $-76.4M | $98.7M | $143.9M | |
| Shares Out. (M) | 0.91 | 0.92 | 1.12 | 1.85 | 3.98 | 29.77 | 34.49 | 35.45 | 46.25 | 57.26 | 60.23 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $16.8M | $10.9M | $18.4M | $3.2M | $4.2M | $112.3M | $65.5M | $43.0M | $33.8M | $62.4M | $95.6M | |
| Marketable Securities | $51.0M | $31.4M | $3.3M | $0.00 | $0.00 | $0.00 | $17.4M | $24.7M | $35.7M | $128.6M | $105.0M | |
| Total Current Assets | $74.4M | $45.9M | $23.7M | $7.0M | $8.4M | $115.1M | $92.8M | $86.9M | $86.0M | $223.0M | $230.0M | |
| Total Assets | $84.9M | $52.5M | $26.7M | $10.5M | $11.2M | $132.9M | $115.3M | $172.3M | $178.1M | $284.7M | $278.6M | |
| Total Current Liabilities | $6.6M | $11.5M | $12.0M | $5.4M | $7.5M | $4.2M | $12.0M | $73.7M | $34.1M | $39.3M | $47.0M | |
| Long-Term Debt | $91.2M | $89.4M | $78.1M | $77.3M | $68.0M | $0.00 | $12.8M | $5.1M | $59.5M | $61.9M | $0.00 | |
| Total Liabilities | $103.6M | $110.0M | $93.3M | $85.0M | $77.6M | $5.8M | $40.2M | $110.5M | $138.5M | $130.1M | $72.8M | |
| Stockholders' Equity | $-18.7M | $-57.5M | $-66.6M | $-74.5M | $-66.4M | $127.1M | $75.1M | $61.9M | $39.7M | $154.7M | $205.8M | |
| Retained Earnings | $-121.3M | $-164.7M | $-221.2M | $-245.7M | $-258.5M | $-267.0M | $-353.7M | $-399.8M | $-505.3M | $-422.1M | $-384.2M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $-29.8M | $-33.1M | $-54.2M | $-23.7M | $-1.9M | $10.4M | $-18.7M | $-33.5M | $-69.7M | $-1.6M | $12.8M | |
| Capital Expenditure | $-643.0K | $-181.0K | $-21.0K | $-26.0K | $-33.0K | $-102.0K | $-93.0K | $-296.0K | $0.00 | $-835.0K | $-771.0K | |
| Free Cash Flow | $-30.4M | $-33.3M | $-54.2M | $-23.8M | $-2.0M | $10.3M | $-18.8M | $-33.8M | $-69.7M | $-2.4M | $12.0M | |
| Investing Cash Flow | $-45.8M | $27.4M | $33.3M | $3.2M | $-33.0K | $-15.5M | $-36.7M | $-17.4M | $-22.2M | $18.1M | $87.2M | |
| Financing Cash Flow | $61.2M | $-203.0K | $28.0M | $4.9M | $2.7M | $113.1M | $8.4M | $28.5M | $82.1M | $12.1M | $-42.3M | |
| Issuance of Stock | $0.00 | $0.00 | $28.3M | $0.00 | $0.00 | $49.3M | $0.00 | $6.1M | $64.5M | $8.6M | $8.6M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-2.8M | $-4.7M | $-3.4M | $0.00 | $0.00 | $0.00 | |
| Issuance of Debt | $82.8M | $0.00 | $0.00 | $5.4M | $3.1M | $0.00 | $12.8M | $42.4M | $59.0M | $0.00 | $0.00 | |
| Payments of Debt | $-20.6M | $-157.0K | $-193.0K | $-207.0K | $-227.0K | $-38.1M | $-16.0K | $-17.5M | $-42.7M | $0.00 | $-60.1M | |
| Stock Based Comp. | $6.6M | $4.6M | $6.5M | $4.4M | $2.5M | $2.4M | $4.3M | $6.0M | $14.9M | $12.6M | $12.6M | |
| Net Change in Cash | $-14.5M | $-5.9M | $7.1M | $-15.6M | $767.0K | $108.0M | $-46.9M | $-22.4M | $-9.3M | $28.6M | $58.3M |
Dilution Tracker
Shares outstanding grew 102.3% over 5 years — significant dilution
Shares Outstanding
60M
5-Year Share Growth
+102.3%
Stock Issuance (TTM)
$8.6M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.91 | 0.92 | 1.12 | 1.85 | 3.98 | 29.77 | 34.49 | 35.45 | 46.25 | 57.26 | 60.23 | |
| YoY Change % | — | 0.4% | 22.4% | 65.3% | 114.8% | 647.7% | 15.9% | 2.8% | 30.5% | 23.8% | 5.2% | |
| Stock Issuance | $0.00 | $0.00 | $28.3M | $0.00 | $0.00 | $49.3M | $0.00 | $6.1M | $64.5M | $8.6M | $8.6M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-2.8M | $-4.7M | $-3.4M | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $6.6M | $4.6M | $6.5M | $4.4M | $2.5M | $2.4M | $4.3M | $6.0M | $14.9M | $12.6M | $12.6M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 0.0% | 0.0% | 0.0% | 77.1% | 90.2% | 92.8% | 97.8% | 92.1% | 68.6% | 84.5% | 86.1% | |
| Operating Margin % | 0.0% | 0.0% | 0.0% | -158.4% | -36.0% | 27.0% | -245.1% | -180.6% | -368.5% | -4.0% | 8.2% | |
| Net Margin % | 0.0% | 0.0% | 0.0% | -191.0% | -96.0% | -29.9% | -263.5% | -167.7% | -446.9% | 78.2% | 101.6% | |
| EBITDA Margin % | 0.0% | 0.0% | 0.0% | -138.1% | -40.9% | -27.5% | -251.2% | -158.6% | -323.6% | 92.7% | 117.7% | |
| FCF Margin % | 0.0% | 0.0% | 0.0% | -185.1% | -14.8% | 36.1% | -185.1% | -123.2% | -295.0% | -2.3% | 9.8% | |
| ROE % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -28.2% | -26.5% | -67.2% | -207.8% | 85.7% | 95.3% | |
| ROA % | -23.7% | -63.2% | -142.6% | -131.7% | -117.5% | -11.9% | -21.6% | -32.0% | -60.2% | 36.0% | 49.2% | |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - | - |
Valuation
P/E (TTM)6.70
Historical4.72 / 6.74 / 24.47
Industry Med.27.41
P/S6.33
Historical0.38 / 6.53 / 23.09
Industry Med.9.51
P/B3.83
Historical1.16 / 3.09 / 12.35
Industry Med.2.93
EV/EBITDA4.09
Historical-367.81 / -5.23 / 380.25
Industry Med.13.14
EV/Revenue4.82
Historical2.02 / 7.05 / 19.06
Industry Med.8.71
P/FCF66.34
Historical11.26 / 46.94 / 86.24
Industry Med.27.54
Intrinsic Value Models
Tangible Book
$3.30
Net Current Assets
$2.660
Net-Net Working Capital
$2.28
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PE Ratio | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | 6.64 | 6.70 | |
| PS Ratio | - | - | - | 0.88 | 3.36 | 9.04 | 15.56 | 8.45 | 16.32 | 4.82 | 6.33 | |
| PB Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.40 | 2.11 | 4.40 | 11.29 | 3.29 | 3.83 | |
| EV/EBITDA | -7.30 | -3.09 | -2.18 | -5.08 | -21.57 | -24.62 | -3.52 | -5.70 | -5.74 | 3.87 | 4.09 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 7.02 | 8.82 | 6.78 | 8.84 | 9.03 | 18.57 | 3.58 | 4.82 |
Analyst Estimates & Quality
Altman Z-Score
7.47
Safe
Piotroski F-Score
7
Strong
Beneish M-Score
-1.21
Possible Manipulator
Forward Estimates
| Metric | Current Year | Next Year | 2 Years Out |
|---|---|---|---|
| Revenue | $146.8M | $180.3M | $259.9M |
| Net Income | $63.8M | $57.4M | $123.8M |
| EPS | 1.03 | 0.90 | 1.98 |
| Book Value per Share | 3.52 | 4.48 | 6.06 |
| Operating Cash Flow per Share | 0.81 | 0.92 | 1.50 |
| Operating CF | $48.79M | $55.41M | $90.35M |
Dividends
Revenue Segments
By Business
| Segment | 2025 |
|---|---|
| Research and development, manufacturing, commercialization and sale of innovative medicines and | $106.5M |
By Geography
| Segment | 2025 |
|---|---|
| United States | $106.5M |